Meril Life Sciences today announced one-year results from a pivotal trial evaluating its balloon-expandable Myval THV system.

Meril Life Sciences announced one-year results from its pivotal LANDMARK trial, presented during the prestigious ...

This week, a number of companies, big and small, shared updates on their cardiovascular technology innovations at EuroPCR ...

Looking toward approval in the US, larger studies with careful hemodynamic data will be needed, says Martin Leon.

The Myval THV series demonstrated non-inferiority to contemporary THVs in terms of 1-year clinical efficacy composite endpoint (Myval THV Series: 13% vs. Contemporary THV: 13.1%, difference: -0.1% ...

First-of-its-kind head-to-head TAVI trial reinforces the performance and safety of the Next Gen Myval THV series VAPI, India, May 22, 2025 /PRNewswire/ -- Meril Life Sciences announced one-year ...

Mr. Sanjeev Bhatt, Senior Vice President – Corporate Strategy at Meril, said: "The LANDMARK trial represents a significant milestone not just for Meril, but for the global TAVI community.